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Abstract
Heparin-derivative anticoagulants include unfractionated heparin (UFH), low 
molecular weight heparin (LMWH), pentasaccharide (fondaparinux), and ultralow 
molecular weight heparin (ULMWH). Heparin contains an active pentasaccharide 
sequence that binds to antithrombin (AT). This bond produces conformational 
changes that accelerate its binding with AT and inactivation of coagulation factors 
XIIa, XIa, Xa, and IXa and thrombin (IIa). Thrombin and factor Xa are the most 
sensitive to inhibition by the heparin-AT complex, and the strength of inhibit-
ing thrombin is ten times more sensitive than factor Xa. The UFH anticoagulant 
response is monitored using activated partial thromboplastin time (APTT), a 
measurement that is sensitive to inhibition of thrombin and factor Xa. Protamine 
titration examination is the standard for measuring UFH concentrations in plasma. 
Recommendations from the American College of Chest Physicians (ACCP) suggest 
that the APTT target range for the UFH therapy is equivalent to 0.2–0.4 IU/mL with 
protamine titration or 0.35–0.7 IU/mL with an anti-Xa examination. A new exami-
nation is thrombodynamics (TD), measuring the level of development of clots. This 
method is considered most able to mimic the coagulation process that occurs in vivo 
compared to other examinations.
Keywords: heparin, anticoagulant, PPT, APTT, anti-Xa, protamine, 
thrombodynamics
1. Introduction
At present the use of anticoagulants is very wide; about 0.7% of the popula-
tion in the west receives anticoagulant treatment. Basic anticoagulant therapy is 
a vitamin K antagonist; a derivative of warfarin, which is most commonly used, 
is coumadin (warfarin). This drug has been used for more than 50 years and is 
consistently able to eliminate recurrent venous thrombosis at adequate doses. 
However, warfarin has disadvantages, namely, the interaction with other drugs 
and with food, slow onset and excessive effects, and a narrow therapeutic range. 
Drug responses and pharmacodynamics are varied and unpredictable, so routine 
monitoring is needed. For most patients who take drugs in the long term, this is 
quite troublesome [1].
The current world medical need is to find anticoagulants that are more effective 
and safer than warfarin for both doctors and patients in long-term use. Responding 
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to this need, a new drug is needed that can change molecules that are difficult to 
absorb to be easily absorbed through the digestive tract; this is used as the basis for 
making oral preparations of unfractionated heparin (UFH). In theory the use of 
the oral form of heparin or low molecular weight heparin (LMWH) is given at fixed 
doses, two or three times a day, and does not require overly frequent coagulation 
monitoring checks or dosage adjustments which are too tight, and the potential 
for interactions between drugs and medications is also low, making this drug an 
anticoagulant needed for long-term use [1].
Coagulation monitoring for patients receiving heparin therapy is very impor-
tant. This is intended to obtain a range of heparin therapy that is effective in 
reducing the incidence of thrombus and bleeding. The effective use of heparin anti-
coagulant therapy must increase the activated partial thromboplastin time (APTT) 
value from 1.5 to 2.5 times. This value is equivalent to levels of heparin 0.2–0.4 U/mL 
based on protamine titration and is equivalent to anti-Xa levels 0.3–0.7 U/mL [2]. 
This chapter will discuss laboratory tests that are used to monitor patients receiving 
heparin therapy.
2. Development of heparin
Heparin is the oldest anticoagulant used in medicine. Heparin was discovered 
by McLean in 1916 while trying to isolate thromboplastic agents. Heparin is a 
polysaccharide from the class of glycosaminoglycans (GAG) which naturally 
appears on all mast cells. Further research in 1935 resulted in clinical use of 
heparin. Since then, heparin has been widely studied for various applications and 
modifications [3].
Unfractionated heparin (UFH) is a product of GAG purified from animal tissue, 
most often from pig intestines. Heparin provides indirect anticoagulant proper-
ties by binding to antithrombin III (ATIII) and facilitating the inhibitory effects 
possessed by AT on thrombin and activated X factor (factor Xa). It is known that 
only UFH contains at least 18 saccharide sequences that can affect AT activity and 
thrombin, whereas UFH with a series of certain pentasaccharides can inhibit the 
activity of factor Xa [3] (Figure 1).
The heterogeneity of the structure of the UFH causes extensive bioactivity 
and physiological activity. Some heparin chains bind to other plasma proteins and 
have an effect on bone metabolism resulting in osteoporosis or heparin-induced 
thrombocytopenia (HIT) and other unpredictable effects that require continuous 
monitoring. Further research and discoveries resulted in low molecular weight 
heparins (LMWH) in the late 1970s to early 1980s; this was to find anticoagulants 
which were more predictable in their activities [4]. LMWH, such as enoxaparin, 
dalteparin, and tinzaparin, is made by chemical control or enzymatic cutting of 
UFH in a depolymerization reaction.
This controlled process produces fragments with lower molecular weight and 
more predictable action than UFH. As a result, side effects are lighter than UFH, 
monitoring needs are decreased, and bioavailability increases, making LMWH 
potentially used for outpatients. This makes LMWH the standard of care replacing 
UFH except in certain cases such as kidney failure and acute coronary syndrome 
where UFH is still preferred because the liver clearance is lighter and better revers-
ible with protamine sulfate [5].
Ultralow molecular weight heparin (ULMWH) was discovered in early 2000 
through a process of chemical synthesis. The reason is to get agents with lighter side 
effects but have the same or better anticoagulant effect which causes a higher anti-
factor Xa ratio to antithrombin activity [6].
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3. Structure and biosynthesis of heparin
Heparin is a polydisperse and highly sulfated GAG with a molecular weight 
between 5 and 40 kDa. The structure of the complex contains repetitive disaccha-
ride units that contain uronic acid residues (l-iduronic (IdoA) or d-glucuronic acid 
(GlcA)) and N-acetyl-d-glucosamine. The biosynthesis process of heparin starts 
in the endoplasmic reticulum and the Golgi apparatus of mast cells. The tetrasac-
charide link attaches to the residue of serine in the core protein, serglycin, and 
then adds a unit of d-glucuronic acid (1→4) N-acetyl-d-glucosamine disaccharide. 
Disaccharide sulfonation and epimerization of glucoronate to iduronate are carried 
out by various enzymes in the biosynthetic pathway. In total there are 12 enzymes 
involved in this pathway, which act together to form the desired molecule. These 
involved enzymes have many isoforms, which cause heterogeneity of heparin and 
allow these enzymes to directly biosynthesize associated GAG, heparin sulfate. The 
degree of sulfation and sulfate residue allocation depends on the spectrum of activ-
ity of the product. In mast cell degradation, peptidoglycan heparin changes to GAG 
heparin through protease and β-endo glucuronidase activity [3].
The first glycosaminoglycan-protein bonding region is formed due to gly-
cotransferase activity. Repeated disaccharide units undergo elongation by GlcA and 
GLcNAc transferase. Modified chains include N-deacetylation and N-sulfonation, 
O-sulfonation, and epimerization, which then occur due to specific enzyme activ-
ity. The monosaccharide symbol in this figure follows the symbol nomenclature for 
glycan (SFNG) system [3] (Figure 2).
Figure 1. 
Mechanism of heparin in the coagulation cascade. Box A: AT (red) binds to a heparin fragment (green) with 
any series length provided that certain pentasaccharide bonds can inhibit factor Xa. Box B: AT (red) binds to 
heparin (green) with a chain length > 17 U of disaccharide that can inhibit thrombin (factor IIa) [3].
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4. Mechanism of heparin as an anticoagulant
Heparin has anticoagulant effects through interactions with coagulation factors 
and inhibitors. Coagulation is a complex process involving proteins, platelets, and 
cellular components such as endothelium and monocytes. The balance of hemosta-
sis is maintained if the activity of procoagulant can be balanced with an inhibitor. 
The main inhibitor of plasma coagulation factor is AT, which acts on active coagula-
tion factors such as FXIIa, FXIa, FXa, FIXa, FVIIa, and FIIa. These coagulation 
factors are serine proteases, so AT is a serine protease inhibitor (serpin).
Heparin, acting as a catalyst, provides anticoagulation activity by potentiating 
other AT and serpin inhibitor activities (Figure 3). The interaction of heparin with 
AT requires a certain sequence of pentasaccharides, but not so with other serpins. 
Figure 2. 
Heparin biosynthesis.
Figure 3. 
Interaction of the coagulation factor with serpin. The blue line shows the place of inhibition of each serpin [11]. 
TFPI, tissue factor pathway inhibitor; AT, antithrombin; HCII, heparin cofactor II.
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Another important heparin-binding inhibitor on the extrinsic pathway is tissue 
factor pathway inhibitors (TFPI) [7–9].
Antithrombin (AT) under conditions when it does not bind to heparin is a slow-
acting serpin, because the reactive center loop is partially folded to the center of 
the b-sheet structure. When binding to heparin, AT inhibition activity will increase 
significantly, which is a characteristic of serpin. The high-affinity pentasaccharides 
in heparin bind to antithrombin through two stages: first, the initial binding process 
involves three monosaccharide units and initiates conformational changes to AT, 
and then after the interaction is complete, AT conformation after activation by 
heparin is stabilized. This conformational change is transmitted to the AT structure, 
causing the opening of the reactive center loop and an increase in exosite exposure 
from AT which binds directly to FXa [10].
4.1 Inhibition of antithrombin in factors IIa and Xa
Active AT conformation caused by pentasaccharides is sufficient to increase 
inhibitory activity in FXa, a protease that converts prothrombin to thrombin (FIIa). 
Factor Xa interacts directly with AT in specific exosite exposed when binding to hep-
arin. In addition, in the presence of calcium, a single heparin chain can bind directly 
to AT and FXa, increasing AT-FXa interactions, but this is not absolutely necessary. 
This calcium-dependent effect can account for reports of calcium-induced-specific 
molecules during the FXa inhibition process by AT [12]. Heparin-mediated FXa 
binds to AT, indicating the longer heparin chain will increase its affinity with the 
presence of Ca2+ and will strengthen inhibition [13].
Unlike FXa, the potentiation of thrombin inhibition by AT requires an additional 
13 saccharide chains attached to the nonreductive end of the pentasaccharide 
sequence, so thrombin and AT are bound to the same heparin molecule. Thrombin 
interacts with heparin in exosite II, which is basically a different method with AT; 
no specific heparin is needed for this interaction [14].
4.2 Inhibition of antithrombin in other coagulation factors
Antithrombin also inhibits several other protease coagulant factors. The way 
antithrombin blocks FIXa is similar to FXa, which binds to the same exosite on 
AT. The high-resolution crystal structure of the pentasaccharide-FIXa-AT complex 
shows that one pentasaccharide binds to AT and the second binds to exosite from 
FXa, which allows a relationship between the two proteins with one molecule of 
heparin [13].
The ability of heparin to increase AT inhibition in FXI and kallikrein in the 
intrinsic coagulation pathway is relatively limited compared to FXa and thrombin. 
It should be noted that FXI activity in AT mutants that bind to the heparin site is 
still slightly potentiated by heparin, suggesting that there is a direct interaction 
between heparin and FXI involved in the binding sites of potential heparin found in 
the FXI catalytic domain [11].
Antithrombin inhibits the FVIIa complex in the extrinsic pathway, and this 
effect is reinforced by fondaparinux, LMWH, and UFH. Direct and calcium-depen-
dent interactions are found between FVIIa and heparin [11].
4.3 Other serpins activated by heparin
Heparin cofactor II (HCII), another serpin potentiated by heparin, is a 
coagulation inhibitor that only inhibits thrombin. HCII is also reported to inhibit 
chymotrypsin and neutrophil cathepsin G. Heparin cofactor II is found in plasma 
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at the same level as AT, but HCII cannot replace AT if there is a deficiency. HCII 
deficiency has no effect on the coagulation system but results in increased forma-
tion of an occlusive arterial thrombus after endothelial damage. In vivo HCII is 
potentiated by dermatan sulfate, which is found in the walls of blood vessels. HCII 
activated by dermatan sulfate may play a role in preventing excessive thrombosis 
of injured blood vessels [15].
Heparin and dermatan sulfate both potentiate inhibition of thrombin through 
HCII in several stages. Unlike AT, HCII does not require a certain series of heparin 
to interact. Other polyanions can also bind to HCII. The HCII bond with heparin 
causes conformational changes similar to AT while also releasing thrombin-binding 
N-terminal tail. The combination of reactive center loop expulsion initiated by GAG 
by exposure to exosite protease-binding is controlled by AT and HCII in the oppo-
site way [16, 17].
Protein C inhibitors (PCI) regulate the activity of activated protein C (APC), 
which is the active form of zymogen protein C. Protein C is converted to APC by 
thrombin and in its active form acts as an anticoagulant by inactivating FVa and 
FVIIIa, in the presence of protein cofactors S. PCI regulates coagulation inhibitors, 
in this case acting more as a supporter of coagulation than inhibiting coagulation. 
The bond of heparin to PCI strengthens the inhibition of APC and FXa in the pres-
ence of calcium. A long chain of heparin is needed to strengthen APC inhibition, 
which suggests both PCI and protease require simultaneous bonding with heparin. 
The basic structure of the PCI complex with heparin and thrombin if separated, 
binding sites for heparin will appear involving the H helix, which is located close to 
the reactive loop [18].
The importance of protease nexin (PN)-1 in the last biology and hemostasis 
is known. In vitro serpin is known to have an effect of approximately 100 times 
faster than AT, and heparin increases about 3 times. In vivo PN-1 does not con-
tribute to the activity of heparin as an anticoagulant because its concentration in 
plasma is very low; on the contrary, PN-1 is found to bind to the cell surface in 
several organs and tissues, including blood vessel walls. Protease nexin (PN)-1 is 
detected in platelet granules on the platelet surface and secreted during platelet 
activation. In this context, the contribution of PN-1 to antithrombotic activity 
from heparin in vivo is ignored [19].
The crystal structure of PN-1 is obtained from the breakdown of complexes 
with heparin and thrombin. This protein has a typical serpin fold with the 
heparin-binding site in helix D. Contrary to AT, heparin-binding site PN-1 and 
thrombin are not parallel when the reactive center loop of PN-1 productively 
interacts with the active part of thrombin. The initial formation of the ternary 
complex between PN-1 and thrombin and heparin can be said to be the initial 
phase of two-phase interaction, with loss of heparin-thrombin interactions when 
covalent complex PN-1 thrombin is formed. Heparin is not released when forming 
the PN-1-thrombin complex; this shows that the PN-1-thrombin complex is still 
bound to HS on the cell surface [11, 20].
Protein Z-dependent proteinase inhibitors are known to inhibit both FXa and 
FXIa. Heparin speeds up this reaction 20–100×. The heparin-binding site on protein 
Z-dependent protease inhibitors involves basic residues in helix D (such as AT) and 
helix C (unlike AT), and the presence of unstructured N-terminal ends can indicate 
similarities with HCII [21].
Other serpins, c1inh, inhibit both the complement cascade and the intrinsic 
pathway, where the coagulation system and innate immune system interact. Clinical 
deficiency leads to congenital angioedema through excessive contact system activ-
ity. The effects of c1inh are not limited to complement and contact systems. Heparin 
potentiates the activity of the c1inh, and the crystal structure of the c1inh indicates 
7Examination of Laboratory for Monitoring Heparin Anticoagulant Therapy
DOI: http://dx.doi.org/10.5772/intechopen.88401
a different model of activity against different protease and heparin-binding sites 
against AT [22].
4.4 Non-serpin inhibitors: tissue factor pathway inhibitors
Tissue factor pathway inhibitors (TFPI) are structurally serpin, but not serine 
protease inhibitors. Tissue factor pathway inhibitors (TFPI) are major inhibi-
tors in the extrinsic pathway. The heparin-binding TFPIα isoform contains an 
acidic N-terminal region, three Kunitz domain pairs, and a basic C-terminal 
end. Kunitz domain is involved in anticoagulant activity, with the first domain 
inhibiting the FVIIa-tissue factor complex and the second domain inhibiting FXa. 
The C-terminal circuit in TFPI has a high affinity for heparin. Heparin injection 
releases TFPI bound to the endothelium to the circulation. Heparin bound to 
TFPI potentiates inhibitory activity in both free FXa and FXa in the FVIIa-TF-FXa 
complex [11].
5. The drug derivate heparin
5.1 Unfractionated heparin
Unfractionated heparin (UFH) is one of the most commonly used parenteral 
anticoagulants to treat or prevent thromboembolism and has been used for almost a 
century. This drug is used in various methods, such as systemic use, through a cath-
eter, extracorporeal, or on the surface of a medical device to prevent thrombotic 
complications. Heparin depends on the presence of antithrombin (AT) to inhibit 
clotting factors, so heparin is called an anticoagulant which acts indirectly. Heparin 
does not have fibrinolytic activity and will not lyse the thrombus [23].
Heparin contains an active pentasaccharide sequence that binds AT. The 
active pentasaccharide sequence responsible for catalyzing AT is found in one 
third and one tenth of the UFH and LMWH chains. After heparin binds and acti-
vates AT, heparin can release AT and bind other ATs, thus providing a continuous 
anticoagulant effect. This bond produces conformational changes that accelerate 
binding of AT and inactivation of coagulation factors XIIa, XIa, Xa, and IXa and 
thrombin (IIa). Thrombin and factor Xa are the most sensitive to inhibition by 
the heparin/AT, and tenfold thrombin complex is more sensitive to inhibition 
than factor Xa [23, 24].
The inhibition of UFH on thrombin requires binding of coagulation enzymes 
and AT through high-affinity pentasaccharides, whereas inhibition of factor Xa 
requires only heparin binding to AT. By deactivating thrombin, heparin not only 
prevents fibrin formation but also inhibits platelet activation induced by throm-
bin and coagulation factors V and VIII. In addition to its anticoagulation effects, 
heparin increases the permeability of blood vessel walls, suppresses smooth muscle 
proliferation, suppresses osteoblast formation, and activates osteoclasts [23, 24].
5.1.1 Pharmacokinetics and pharmacodynamics
Intravenous (IV) or subcutaneous (SC) injection is the route available for UFH 
administration, and IV is the most frequently used route. When given by SC injec-
tion for therapeutic anticoagulation, the dose must be large enough (30,000 U/day) 
to compensate for the low bioavailability of UFH, as can be seen in Table 1. UFH 
is already bound to plasma proteins, which results in variations in anticoagulant 
responses [25].
Anticoagulation Drugs - The Current State of the Art
8
UFH clearance depends on the dose and occurs through two independent 
mechanisms. The initial phase is a fast and saturated bond in endothelial cells, 
macrophages, and local proteins where UFH is depolymerized. The second phase is 
slower and unsaturated clearance through the kidneys. At therapeutic doses, UFH 
is cleared mainly through depolymerization, where higher molecular weight chains 
are cleared faster than those with lower weight. When clearance tends to the kidneys, 
an increase or extension of the dose of UFH provides a disproportionate increase in 
both the intensity and duration of the anticoagulant effect. Anticoagulant responses 
to UFH administration are usually monitored using activated partial thromboplastin 
time (APTT). APTT must be measured every 6 hours with IV administration and 
the dose adjusted until the patient has reached a stable level of therapy. After a stable 
condition is reached, the frequency of monitoring can be extended [24, 26].
5.1.2 Monitoring
The UFH anticoagulant response is monitored using APTT, a measurement that is 
sensitive to inhibition of thrombin and FXa. APTT examinations have a large variety 
of reagents (even the same reagents have different lots) so that they have varying 
sensitivity to the anticoagulant effect of UFH. Each laboratory must ensure that their 
therapeutic range of heparin and APTT is based on levels of heparin measured by anti-
Xa (target range 0.3–0.7 U/mL) or protamine titration (0.2–0.4 U/mL). APTT must 
be measured every 6 h based on UFH half-life and the dose adjusted until the patient 
reaches the therapeutic level based on the APTT target range. When APTT values are 
obtained in the treatment range twice in a row, monitoring can be extended to one or 
two times a day depending on the clinical scenario. Weight-based dose nomograms, 
consisting of bolus doses and infusion droplet speeds with regular monitoring using 
APTT, are recommended for the treatment of thromboembolic disease [25].
The UFH dose nomogram differs in each hospital due to differences in thrombo-
plastin reagents, calibration, and interlaboratory standards in APTT measurements. 
This causes the need for alternative monitoring methods. Functional heparin, also 
known as anti-Xa, has been promoted as a more reliable measure of UFH because 
it is not sensitive to factors other than UFH, such as concomitant use of warfarin, 
sodium citrate in the sample tube, impaired lupus anticoagulant (LA), increased 
factor activity VIII, and liver disease [25].
Acquired inhibitors, such as LA, cause an extension of APTT, which results 
in not being able to accurately measure the level of anticoagulation due to UFH. 
Characteristics Heparin LMWH
Origin Pig intestine Pig intestine
Molecular weight (Da) 15,000 5000
Target Xa:IIa Xa > IIa
Bioavailability (%) 30 90
Half-life (h)a IV depends on doses 1–3 3–7
SC depends on doses 2–5
Reversal by protamine Complete Partial (60–80%)
Renal excretion Depends on dose Yes
Occurrence of heparin-induced thrombocytopenia (%) <5.0 <1.0
a In normal renal function.
Table 1. 
Pharmacological properties of UFH and LMWH [26].
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In this case, if APTT is maintained within the usual therapeutic range, it may 
result in underdose of UFH and cause development or recurrence of thrombosis. 
Simultaneous testing of APTT and anti-Xa levels is needed to estimate the APTT 
value of therapy in patients receiving heparin [27].
5.2 Low molecular weight heparin (LMWH)
LMWH is a polysaccharide derived from the pig’s intestine containing an 
active pentasaccharide sequence which is needed for anticoagulant activity as in 
UFH. LMWH is produced from UFH through chemical or enzymatic degradation. 
Each LMWH product is prepared by a different method. Clinical development of 
LMWH driven by certain observations includes the reduction of thrombin activ-
ity in relation to anti-factor Xa activity, the ratio of benefits or risks that are more 
favorable in animal studies, and good pharmacokinetic properties. The molecular 
weight of the LMWH is approximately one third of the molecular weight of UFH 
(4000–5000 Da). Because of their smaller size, LMWH has a lower affinity for 
thrombin because they cannot bind AT and thrombin together. However, LMWH 
has the same affinity as UFH for FXa [23].
Factor Xa does not require heparin to stabilize its interaction with AT, so smaller 
molecules such as LMWH deactivate factor Xa equivalent to larger molecules such as 
UFH. The length of the polysaccharide chain of at least 18 saccharides, including the 
order of active pentasaccharides, is needed to bridge between AT and thrombin. About 
25–50% of LMWH molecules are above the length of this chain. All LMWH chains 
contain active pentasaccharide sequences, so 100% can inactivate factor Xa [23].
5.2.1 Pharmacodynamics and pharmacokinetics
There are several biological consequences of the small size of LMWH com-
pared to UFH, a decrease in binding of LMWH to other plasma proteins, macro-
phages, and endothelial cells. This resulted in a more predictable dose-response 
relationship and a longer plasma half-life for LMWH. In contrast to UFH, 
routine plasma monitoring is not needed which makes it easier for outpatient 
management. The lower incidence of HIT has also been investigated because 
of the reduced bond to PF4 and platelets. LMWH has also reduced bonds in 
osteoblasts resulting in decreased incidence of osteoclast activation and lower 
bone destruction [23].
All LMWH products have half-lives ranging from 3 to 7 h and bioavailability 
87–90%. Anti-Xa peak activity occurs 3–5 h after SC injection with predictable 
dose-based responses. All agents are metabolized through desulfation or depoly-
merization, and all agents metabolized are excreted through the kidneys [25].
5.3 Pentasaccharides (fondaparinux)
Fondaparinux is a chemically synthesized anticoagulant that is specifically 
developed as a selective indirect inhibitor for FXa. Factor Xa is an important target 
for anticoagulant therapy given its position at the meeting of the intrinsic and 
extrinsic coagulation pathways. Its inhibition significantly decreases thrombin 
formation [28] (Figure 4).
Factor Xa has one function in the coagulation cascade, as a gatekeeper to the 
path along the coagulation cascade. Conversely, thrombin (FIIa) has many roles in 
the coagulation process, including activation and mediation of endogenous anti-
coagulation by binding to thrombomodulin and activation of protein C. Factor Xa 
may be a purer target than thrombin [29].
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5.3.1 Pharmacodynamics and pharmacokinetics
Fondaparinux binds non-covalently and reversibly to AT, increasing AT antico-
agulant activity by up to 300 times. The AT-fondaparinux complex then binds and 
neutralizes FXa, which reduces prothrombin (FII) conversion to thrombin (FIIa), 
thereby inhibiting clot formation. Fondaparinux is then released and can catalyze 
other AT molecules. When AT plasma becomes saturated, excess unbound circulating 
fondaparinux (which has no anticoagulant activity) is excreted through the kidneys.
Because it does not affect pre-existing thrombin circulation, fondaparinux 
may in theory have some residual hemostatics, if needed, at the site of injury. 
Fondaparinux has no effect on the examination of fibrinogen platelet function, 
thrombin time, or antithrombin tests. Fondaparinux can affect PT and APTT 
and can interfere with factor VIII testing. Although not routinely recommended, 
if measurements of fondaparinux are needed (e.g., changes in kidney function, 
weight, or extreme age), the most accurate plasma concentration is measured 
using the anti-factor Xa test. The results of this examination are in IU/mL, which is 
directly proportional to the plasma concentration of fondaparinux. The results were 
extrapolated to the mcg/mL plasma concentration using a standard curve calibrated 
by fondaparinux. The test must be calibrated specifically for fondaparinux, because 
the use of calibration for UFH or LMWH will produce inaccurate results.
Figure 4. 
Formation of antithrombin complexes with FIIa and FXa. (1) Antithrombin (AT), active thrombin (FIIa), 
active X factor (FXa). (2) UFH (chain shape) forms a complex with AT both in FIIa and FXa. (3) Shorter 
polysaccharides of 18 U form AT complex with FXa but not with FIIa. (4) The sequence of pentasaccharides 
forms a bond with FXa only [30].
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The use of fondaparinux and drugs that affect concomitant coagulation (e.g., 
antiplatelet, NSAIDs) results in pharmacodynamic drug interactions that can 
increase the risk of bleeding and should be avoided as much as possible. After stop-
ping fondaparinux, the anticoagulant effect will last up to 4 days and even longer in 
patients with low clearance [31].
Fondaparinux is not absorbed through the gastrointestinal mucosa, so it must 
be given parenterally. Subcutaneous administration showed rapid absorption and 
complete absorption with 100% bioavailability. The peak plasma concentration is 
reached about 2–3 h after subcutaneous administration. A stable state is achieved 
after 3–4 doses of administering fondaparinux once a day [25].
Fondaparinux is highly protein bound and cannot be distributed to tissues 
without binding to proteins. The volume of distribution is 7–11 L, which is close to 
blood volume. Fondaparinux does not undergo metabolism in the liver and is not 
susceptible to the pharmacokinetics of drug interactions with the cytochrome P450 
isoenzyme system substrate [25].
Reduced bonding with macrophages and endothelial cells increases the 
half-life of plasma fondaparinux compared to UFH and LMWH. Elimination of 
fondaparinux is influenced by several patient parameters, including kidney func-
tion, age, and low body weight. These factors must be evaluated regularly, because 
they can block the use of fondaparinux or require increased monitoring for signs 
and symptoms of drug accumulation [25].
5.4 Ultralow molecular heparin
Therapy using LMWH provides clear pharmacokinetic advantages over UFH, 
so LMWH has become the standard of care for prevention and treatment of venous 
thromboembolism (VTE) in patients with and without cancer. The development 
of the ULMWH drug is based on the theory that, because of the much higher ratio 
of anti-Xa and anti-IIa activity, ULMWH will be associated with similar or better 
antithrombotic efficacy from the efficacy achieved by LMWH products but with 
lower bleeding and HIT risks. ULMWH has a molecular weight of <4000 Da and an 
increase in anti-factor Xa activity compared to LMWH. There is only one ULMWH 
marketed outside the United States (bemiparin), and another, RO-14, is currently in 
clinical development [32].
5.4.1 Pharmacokinetics and pharmacodynamics
Bemiparin was approved for once-daily use of subcutaneous VTE primary 
prophylaxis in medical patients and patients undergoing general or orthopedic sur-
gery and for prophylaxis in patients with deep vein thrombosis (DVT). Bemiparin 
originates from alkaline depolymerization and UFH fractionation from pig intesti-
nal mucosa. Pharmacokinetic studies in healthy volunteers given bemiparin showed 
an increase in anti-factor Xa activity depending on the dose given [32].
6. Heparin therapy monitoring
Treatment using UFH requires routine monitoring to see its functional activity 
due to the high variation in plasma concentrations and functional activities after 
fixed doses in each patient. This is due to several reasons, including AT levels in 
plasma that are different in each patient, UFH elimination with two mechanisms 
that also differ in each individual, and neutralization and bonding of heparin with 
various activated plasma proteins and platelets. It is estimated that 10% of people 
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are not sensitive to heparin. The nonlinear pharmacodynamics of UFH make it 
difficult to predict. Unfractionated heparin (UFH) is usually measured by APTT 
or activated coagulation time (for high levels of heparin), but this examination 
has a low sensitivity and is not standardized; besides, this examination is also not 
sensitive to the use of low-dose UFH as prophylaxis. The results also depend on the 
reagent and the instrument used. The reference value for this examination must 
be determined by each laboratory, so it is difficult to compare the results obtained 
from each laboratory [33].
Monitoring the therapy of coagulation UFH activity should be measured 6 h 
after bolus and 6 h after dose change. It takes 6 h for the heparin to reach a stable 
phase, so monitoring heparin therapy less than 6 h after administration gives the 
wrong results for determining the dose. Protamine titration is the gold standard for 
heparin monitoring, but this examination is not widely available and expensive, so 
it is only used for research [34].
Unlike UFH, LMWH has a more stable pharmacokinetics, and its bioavailability 
reaches 100% at any dose with subcutaneous administration. The maximum LMWH 
concentration in plasma is directly proportional to the LMWH dose, and many 
experts believe that routine coagulation monitoring during therapy is not necessary 
because the clinical dose of LMWH can be corrected based solely on the patient’s 
body weight. In a healthy population after a fixed dose of LMWH, it turns out that 
heparin concentration varies and only partially correlates with the patient’s body 
weight. More precisely correction needs to be done in some cases (e.g., low or high 
BMI; critical condition; kidney failure (creatinine clearance <30 ml/min); when 
changing anticoagulants; age (children or elderly >75 years); and pregnancy) [35].
Anti-Xa activity measurement is the most widely used examination for LMWH 
therapy management. This examination has a high sensitivity (lower limit of 
determination using chromogenic substrate is <0.03 anti-Xa IU/mL). This method 
is not a method of global coagulation examination because it only measures the 
concentration of one factor (Xa) but does not react with AT deficiency or changes in 
concentration from other factors that influence patient hemostasis. This method is 
difficult to predict thrombosis or bleeding. Until now there is still no universal and 
reliable method for monitoring heparin properly [30].
6.1 Activated partial thromboplastin time (APTT)
The APTT examination is currently used by most laboratories for monitor-
ing UFH therapy. This examination uses plasma citrate from the patient and is 
measured based on clot formation. Phospholipids and activators are added to 
platelet-poor plasma (PPP) patients and then incubated. Calcium is added and 
then the clotting time is measured. This examination has several advantages, fast, 
inexpensive, and widely available, but this does not directly measure the level of 
heparin. Many APTT reagents are available, and each reagent has a varied response 
to heparin therapy, and besides that several physiological factors can influence the 
results of this examination [36].
The clinical condition of patients can also affect the results of APTT, but it does 
not correlate with the presence of bleeding or thrombosis. The most frequent cases 
are patients receiving vitamin K antagonist therapy. Patients with international nor-
malized ratio (INR) of more than 1.3 because warfarin therapy can also affect APTT 
results in heparin monitoring. Other cases that also affected were patients with 
antiphospholipid antibodies, which could affect clotting tests. Coagulation factor 
deficiencies, such as in patients with liver disease, or consumptive coagulopathy 
in disseminated intravascular coagulopathy (DIC) will affect APTT results. These 
conditions cause heparin anticoagulation activity not to be measured properly [36].
13
Examination of Laboratory for Monitoring Heparin Anticoagulant Therapy
DOI: http://dx.doi.org/10.5772/intechopen.88401
The conditions mentioned above can prolong the APTT results and result 
in underdose anticoagulant doses. Factor VIII and fibrinogen are the most 
frequent causes and can significantly extend or shorten the APTT baseline. 
Patients with acute disease are also known to have a deficiency in antithrombin. 
This condition can lead to excessive anticoagulation when using APTT for 
monitoring [36].
Preanalytic variables also play a role in the APTT response in monitoring hepa-
rin. The wrong APTT results can be due to improper sampling, and less samples also 
make too much citrate concentration in the tube. Underdose therapy causes a high 
risk of thrombosis [37].
Basu et al. [38] conducted a study on patients with venous thromboembolism 
who received heparin therapy and found the risk of recurrent thromboembolism 
associated with the APTT ratio which did not reach 1.5–2.5 times the normal 
value. This ratio is used as a standard for therapeutic ranges. Based on this study, 
the authors mention that the ratio is equivalent to levels of heparin 0.2–0.4 U/
mL based on protamine titration and is equivalent to anti-Xa levels of 0.3–0.7 U/
mL. The range of anti-Xa levels is higher because of heparin clearance. Smaller 
heparin molecules are cleared more slowly, so LMWH has a stronger inhibitory 
effect on factor Xa than thrombin. Examinations that measure anti-factor Xa 
activity, such as anti-Xa examination, will detect higher levels than examinations 
that measure antithrombin activity, such as protamine titration, which utilizes 
thrombin time [30].
Other studies evaluated the upper limit of anti-Xa examinations related 
to the incidence of bleeding. This study produced anti-Xa levels of more than 
0.74–0.88 U/mL related to the incidence of bleeding complications [30]. The 
use of the APTT standard ratio for the range of heparin therapy is difficult 
to apply because the response of each APTT reagent to heparin is different. 
Researchers from the joint study found that APTT corresponds to a concentra-
tion of heparin 0.2–0.4 U/mL with protamine titration, based on the APTT 
reagent used. APTT reagents from other laboratories showed different sensitiv-
ity to heparin, and a ratio of 1.5–2.5 times the normal value did not correlate 
with the concentration of heparin in the therapeutic range. Various types 
of laboratories and reagents can produce an APTT ratio of 1.6–3.7 times the 
normal value, which is equivalent to a level of heparin 0.3 U/mL to a ratio of 
2.4–6.2 times the normal value equivalent to the level of heparin 0.7 U/mL with 
anti-Xa [39].
6.2 Anti-Xa activity assay
Variations in results were also obtained for each anti-Xa examination if 
compared with protamine titration as a reference but far smaller compared to 
APTT. The therapeutic range for this examination will remain to be 0.3–0.7 U/mL, 
although with different machines and reagents. In contrast to APTT, anti-Xa results 
are not affected by poor sampling, also are not affected by factor VIII or fibrinogen, 
and are not affected by deficiency factors in patients with liver disease and con-
sumptive coagulopathy [30].
Anti-Xa assay is not a test of factor X activity or factor X level antigen. This 
examination is also called an anti-factor Xa test or a functional test of heparin. The 
principle of this examination is to monitor indirect factor Xa inhibitors, such as 
LMWH and fondaparinux, or direct factor Xa inhibitor drugs such as rivaroxaban. 
These anticoagulants require monitoring in certain patient populations and in 
certain clinical settings. Each anticoagulant requires its own anti-X curve, and this 
must be done by each laboratory [37].
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Anti-Xa activity assay uses the chromogenic method. The known factor Xa is 
added to platelet-poor plasma, wherein there is heparin. Heparin strengthens the 
inhibition of antithrombin to factor Xa, and the uninhibited factor Xa chromogenic 
substrate is added. This process produces color detected by a spectrophotometer 
and directly proportional to the level of factor Xa. The amount of color correlates 
with the level of heparin in the plasma with the correct heparin curve [36].
Like other tests, the anti-Xa assay is imperfect, with the chromogenic method; 
this examination will be affected by the conditions of the hemolysis, jaundice, 
and lipemic samples, which will affect the ability of the machine to measure and 
distinguish chromogenic reactions. Anti-Xa reagents which are not added with 
antithrombin will make false low heparin concentrations in the condition of 
patients with severe antithrombin deficiency, but there can be a misdiagnosis of 
antithrombin deficiency if antithrombin is added. Viewed from the laboratory 
side, anti-Xa assay is considered expensive and needs special attention in the 
process [36].
6.3 Protamine titration
Protamine is a small protein, rich in arginine, and positively charged, has a simi-
larity to histones, and is involved in folding and stabilizing DNA in sperm heads. 
Protamine can neutralize the effects of heparin through electrostatic bonds between 
cation arginine groups from protamine and heparin anions with a ratio of 1:1. This 
results in a neutral protamine-heparin aggregate which can be seen in the form of 
a white suspense formed in a few seconds. Binding of heparin by protamine will 
release the AT-heparin complex, resulting in AT activity returning to its original 
state [40].
Protamine titration is the gold standard for measuring UFH concentrations 
in plasma. The results of this examination are quite promising, but it is still not 
considered a good examination in terms of clinical management of UFH because 
it is still not automatic. UFH clinical trials determined that heparin concentrations 
of 0.2–0.4 U/mL with protamine titration were equivalent to APTT lengthen-
ing 1.5–2.5 times the normal values, providing safe UFH levels and good patient 
outcomes [41].
The principle of this examination is to measure thrombin clotting time (TCT), 
which is the time required for clot formation after the addition of thrombin to 
plasma. The presence of UFH in plasma will result in TCT prolongation depending 
on the dose used. Protamine competed in binding to UFH, and the results of prot-
amine titration measurements showed the amount of protamine needed to restore 
TCT to baseline [42].
This method is neither expensive nor difficult, but because it is done manually, 
the workload is quite heavy. The results given by this examination are very depen-
dent on two important factors, the operator that works and the origin of thrombin. 
Protamine titration measurements depend on the operator when identifying clot 
formation in the test tube, so efforts to standardize this are difficult. The reproduc-
ibility of results can be achieved by limiting operators who work on checks and 
equating perceptions between operators about the process of forming clots and 
when the test is certain to be completed.
First time this method was found, thrombin used came from rabbits or young 
cattle. Its concentration is determined by identifying the amount of thrombin 
which results in TCT 18–20 s. At present the thrombin used is from humans, so 
it can increase the specificity of this test. Thrombin originating from humans 
has different interactions with plasma patients than thrombin from rabbits and 
young cattle. Thrombin originating from humans also needs to be determined by 
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calculating the amount of thrombin needed to achieve TCT 18–20 s. Each laboratory 
must determine the concentration of thrombin that is needed based on thrombin 
available in each lab [41].
UFH therapy is optimal if the levels are 0.2–0.4 IU/mL based on protamine 
titration. Recommendations from the American College of Chest Physicians 
(ACCP) suggest that the APTT target for the UFH therapy range is equivalent 
to 0.2–0.4 IU/mL with protamine titration of 0.35–0.7 IU/mL with anti-Xa 
assay [23].
This method is carried out at room temperature, plasma samples and protamine 
solutions that have been titrated at each concentration, and thrombin stored in 
ice until it is transferred to the test tube. First take a normal plasma, and leave it 
at room temperature for 30 s. Then the titration solution is added, and thrombin 
is then calculated when the clot is formed. The time obtained will be used as TCT 
baseline. Assay was repeated using a sample of patients with different protamine 
concentrations starting from the highest concentration first (0.9 IU/mL). After 
finding the smallest concentration that still provides TCT baseline, this result 
illustrates the level of heparin in the blood [41].
6.4 Thrombodynamics
A new examination for the coagulation function, thrombodynamics (TD), 
is examined under different circumstances. This TD measures the level of clot 
formation. Coagulation is triggered on the surface of an activator which is bound 
to a space and extends to the plasma layer. The scattered beam increases in the 
area formed by the clot, so clot formation and time needed can be measured. This 
method is considered most able to mimic the coagulation process that occurs 
in vivo compared to other examinations. This examination is very sensitive to the 
conditions of either hypocoagulation or hypercoagulation. Figure 5 shows the 
Figure 5. 
Examination of thrombodynamics simulates the in vivo coagulation process. (a) Plastic cuvette schemes 
and activators that have been added for TD measurements. (b) Photos of the sequence of clot growth from 
spontaneous activator in vitro and clot in a portion of the sample. (c) Schematic image of clot growth from 
damage to blood vessel walls in vivo [44].
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test tube scheme used in TD examination and the formation of clots and com-
pared with the process of clot in vivo [43].
Clot formation curve depends on several parameters obtained: Tlag (time of forma-
tion of clot); Vi (initial speed of formation of clots) and V (speed of formation of clots) 
in clot formation (slope of clot formation curve versus time at 2–6 min and 15–25 min 
from the initial formation of clots for Vi and V); and CS (clot size 30 min after the 
coagulation process is activated). Other important parameters that are also measured 
are the maximum optical density of the formed clot (D) which shows the quality of the 
clot and the time required for the appearance of spontaneous clot (Tsp). The last two 
parameters have important clinical values  because spontaneous clot (which grows not 
from activators on the surface) is only found in serious hypercoagulability states [44].
Heparin anticoagulants form complexes with ATIII and inhibit factors II, X, and 
IX. Research by Sinauridze et al. measure Tlag, Vi, and V parameters in post hip 
surgery patients who get heparin. The result is only Vi and V have significant dif-
ferent results, whereas Tlag has results that are not much different before and after 
heparin is given [44].
7. Conclusion
Heparin monitoring is needed to achieve an adequate dose. Laboratory tests 
for heparin monitoring include APTT examinations especially for UFH, anti-FXa 
activity assays especially for LMWH, protamine titration especially for UFH, and 
thrombodynamic tests that better reflect in vivo conditions.
Abbreviations
ACCP  American College of Chest Physicians
APC activated protein C
APTT activated partial thromboplastin time
AT antithrombin
C1inh C1 inhibitor
DIC disseminated intravascular coagulopathy
DNA deoxyribonucleic acid
GAG glycosaminoglycans
HC II heparin cofactor II
HIT heparin-induced thrombocytopenia
INR international normalized ratio
IV intravenous
LMWH low molecular weight heparin
NSAID nonsteroid anti-inflammatory drug
PCI percutaneous coronary intervention
PCI protein C inhibitor
PF4 platelet factor 4
PN-1 protein nexin-1
PPP platelet-poor plasma
SC subcutaneous
Serpin serine protease inhibitor
SFNG symbol nomenclature for glycans
STEMI ST-segment elevation myocardial infarction
TCT thrombin clotting time
TD thrombodynamics
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TFPI tissue factor pathway inhibitor
UFH unfractionated heparin
ULMWH ultralow molecular weight heparin
VTE venous thromboembolism
Nomenclature
Symbols
CS clot size at 30th minute of the measurement (μm)
D clot density, it is an optical parameter, which is equal to intensity of 
light scattering from a fibrin clot (au)
Tlag time between contact of plasma sample with activator and start 
of clot growth. Tlag characterizes the initiation phase of blood 
coagulation (min)
Tsp time of spontaneous clot formation in plasma sample volume, 
which had no initial contact with activating insert. Spontaneous 
clotting is induced by circulating activators, active coagulation 
factors, and microparticles (min)
V average rate of clot growth. The parameter characterizing the 
propagation phase of blood coagulation (μm/min)
Vi initial rate, it characterizes the initiation phase of clot growth  
(μm/min)
Superscript
a in normal renal function
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